Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Fresenius Kabi Acquires BD’s Rx Business | Contract Pharma

What are you searching for?

Sign in
Breaking News

Fresenius Kabi Acquires BD’s Rx Business

Gains manufacturing plant in Wilson, NC, and the BD Simplist line of prefilled glass syringes

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Fresenius Kabi USA has acquired Becton, Dickinson and Co.’s Rx business, which includes a pharmaceutical manufacturing plant in Wilson, NC, and the BD Simplist line of seven drugs in ready-to-administer prefilled glass syringes.

The companies also signed a 10-year supply and distribution agreement under which Fresenius Kabi will supply BD with a portfolio of intravenous solutions. Both plan to offer a range of IV solutions in the U.S. beginning in 2016. Financial and contract terms were not disclosed.

The NC plant employs 100 people and features advanced pharmaceutical manufacturing and packaging technologies, which was approved by the FDA in 2012. It currently produces seven drugs in ready-to-administer prefilled syringes and has capacity for future growth. Fresenius plans to further invest in the facility to make it a global center of excellence for prefilled syringe production.

“Ready-to-administer, prefilled syringes are a growing segment in health care due to increased focus on medication safety and labor-saving efficiency,” said John Ducker, president and chief executive officer of Fresenius Kabi USA. “They are a natural complement to our portfolio, enabling us to offer customers more choices and a broader range of specialty injectable medicines in vials as well as ready-to-administer presentations.”

“We believe Fresenius Kabi is a better owner for the BD Rx business, because it complements their existing capabilities in the injectable pharmaceutical industry,” said Tom Polen, president of BD’s Medical Segment. “In addition, we look forward to working with Fresenius Kabi to extend our medication management strategy through the addition of a portfolio of IV fluids, which will broaden our clinical and economical end-to-end solutions for our customers and their patients.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics